Catheter ablation of atrial arrhythmias in cardiac amyloidosis: Impact on heart failure and mortality
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0301753 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Philippe Maury und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, University Hospital Toulouse, Toulouse, France. Hauptthemen laut MEDLINE: Atrial Fibrillation, Tachycardia, Supraventricular, Heart Failure, Amyloidosis. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background
Atrial arrhythmias (AA) commonly affect patients with cardiac amyloidosis (CA) and are a contributing risk factor for the development of heart failure (HF). This study sought to investigate the long-term efficacy and impact of catheter ablation on HF progression in patients with CA and AA.
Methods
Thirty-one patients with CA and AA undergoing catheter ablation were retrospectively included (transthyretin—ATTR CA 61% and light chain—AL CA 39%). AA subtypes included atrial fibrillation (AFib) in 22 (paroxysmal in 10 and persistent in 12), atrial flutter (AFl) in 17 and atrial tachycardia (AT) in 11 patients. Long-term AA recurrence rates were evaluated along with the impact of sinus rhythm (SR) maintenance on HF and mortality.
Results
AA recurrence was observed in 14 patients (45%) at a median of 3.5 months (AFib n = 8, AT n = 6, AFl = 0). Post-cardioversion, medical therapy or catheter ablation, 10 patients (32%) remained in permanent AA. Over a median follow-up of 19 months, all-cause mortality was 39% (n = 12): 3 with end-stage HF, 5 due to late complications of CA, 1 sudden cardiac death, 1 stroke, 1 COVID 19 (and one unknown). With maintenance of SR following catheter ablation, significant reductions in serum creatinine and natriuretic peptide levels were observed with improvements in NYHA class. Two patients required hospitalization for HF in the SR maintenance cohort compared to 5 patients in the AA recurrence cohort (p = 0.1). All 3 patients with deaths secondary to HF had AA recurrence compared to 11 out of the 28 patients whom were long-term survivors or deaths not related to HF (p = 0.04). All-cause mortality was not associated with AA recurrence.
Conclusion
This study demonstrates moderate long-term efficacy of SR maintenance with catheter ablation for AA in patients with CA. Improvements in clinical and biological status with positive trends in HF mortality are observed if SR can be maintained.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Cardiology, University Hospital Toulouse, Toulouse, France.
- I2MC, INSERM UMR 1297, Toulouse, France.
- Department of Cardiology, University Hospital Henri Mondor, Creteil, France.
- Clinique Pasteur, Toulouse, France.
- Department of Cardiology, University of Warwick, Coventry, United Kingdom.
ORCID-Profile: Philippe Maury, Hubert Delasnerie, Serge Boveda, Maxime Beneyto
Zitieren
APA
Maury, P., Sanchis, K., Djouadi, K., Cariou, E., Delasnerie, H., Boveda, S., Fournier, P., Itier, R., Mondoly, P., Voglimacci-Stephanopoli, Q., Beneyto, M., Dhanjal, T. S., Rollin, A., Damy, T., Lairez, O., & Lellouche, N. (2024). Catheter ablation of atrial arrhythmias in cardiac amyloidosis: Impact on heart failure and mortality. PLOS ONE. https://doi.org/10.1371/journal.pone.0301753
Vancouver
Maury P, Sanchis K, Djouadi K, Cariou E, Delasnerie H, Boveda S, et al. Catheter ablation of atrial arrhythmias in cardiac amyloidosis: Impact on heart failure and mortality. PLOS ONE. 2024. doi:10.1371/journal.pone.0301753
BibTeX
@article{Maury2024,
author = {Maury, Philippe and Sanchis, Kevin and Djouadi, Kamila and Cariou, Eve and Delasnerie, Hubert and Boveda, Serge and Fournier, Pauline and Itier, Romain and Mondoly, Pierre and Voglimacci-Stephanopoli, Quentin and Beneyto, Maxime and Dhanjal, Tarvinder S and Rollin, Anne and Damy, Thibaud and Lairez, Olivier and Lellouche, Nicolas},
title = {Catheter ablation of atrial arrhythmias in cardiac amyloidosis: Impact on heart failure and mortality},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0301753}
}
EUVIMED